Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhoea: patient selection and reported outcomes

Neuroendocrine tumours (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with symptoms in keeping with carcinoid syndrome; characterised by diarrhoea, flushing and/or wheezing. This review summarises the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life and improvement following treatment with telotristat ethyl is reviewed. This manuscript also provides an overview of current quality of life questionnaires for patients with NETs and addresses unmet needs in this field of patient reported outcomes.